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Introduction
Multiple sclerosis (MS) is a chronic inflammatory 
disease of the central nervous system (CNS) and 
one of the most common causes of neurological 
disability in young adults.1 The majority of MS 
patients initially present with the relapsing-remit-
ting disease (RR-MS) characterized by episodes of 
active disease and periods of clinical inactivity, but 
most will eventually convert to a secondary-pro-
gressive form (SP-MS) characterized by continu-
ous worsening.1
MS results from an interplay between genes and envi-
ronmental factors. The HLA-DRB1*15:01 haplotype 
has been consistently associated with MS, suggesting 
critical role of the human leukocyte antigen (HLA) 
class II molecules in presenting antigens to CD4+ T 
cells.2 The importance of CD4+ T cells has further 
Hypermethylation of MIR21 in CD4+ T cells 
from patients with relapsing-remitting multiple 
sclerosis associates with lower miRNA-21  
levels and concomitant up-regulation of  
its target genes
Sabrina Ruhrmann, Ewoud Ewing, Eliane Piket, Lara Kular, Julio Cesar Cetrulo Lorenzi, 
Sunjay Jude Fernandes, Hiromasa Morikawa, Shahin Aeinehband, Sergi Sayols-Baixeras,  
Stella Aslibekyan, Devin M Absher, Donna K Arnett, Jesper Tegner, David Gomez-Cabrero, 
Fredrik Piehl and Maja Jagodic
Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
caused by genetic and environmental factors. DNA methylation, an epigenetic mechanism that controls 
genome activity, may provide a link between genetic and environmental risk factors.
Objective: We sought to identify DNA methylation changes in CD4+ T cells in patients with relapsing-
remitting (RR-MS) and secondary-progressive (SP-MS) disease and healthy controls (HC).
Methods: We performed DNA methylation analysis in CD4+ T cells from RR-MS, SP-MS, and HC and 
associated identified changes with the nearby risk allele, smoking, age, and gene expression.
Results: We observed significant methylation differences in the VMP1/MIR21 locus, with RR-MS dis-
playing higher methylation compared to SP-MS and HC. VMP1/MIR21 methylation did not correlate 
with a known MS risk variant in VMP1 or smoking but displayed a significant negative correlation with 
age and the levels of mature miR-21 in CD4+ T cells. Accordingly, RR-MS displayed lower levels of 
miR-21 compared to SP-MS, which might reflect differences in age between the groups, and healthy 
individuals and a significant enrichment of up-regulated miR-21 target genes.
Conclusion: Disease-related changes in epigenetic marking of MIR21 in RR-MS lead to differences in 
miR-21 expression with a consequence on miR-21 target genes.
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been supported by their ability to induce MS-like 
pathology in rodents.3 More than 100 non-HLA loci 
have been associated with MS, jointly pointing to 
importance of immune-mediated functions such as 
lymphocyte activation and differentiation.2,4 Smoking 
has also been consistently associated with an increased 
risk of MS, and carriers of HLA-DRB1*15:01 who are 
smokers have 14-fold higher risk compared to non-
smokers and non-carriers.5
Such gene–environment interactions may be mediated 
through epigenetic mechanisms by which the environ-
ment modulates gene expression in a manner that is her-
itable through cell division. DNA methylation, histone 
modifications, nuclear complexes, and non-coding 
RNAs (ncRNAs) comprise main epigenetic mecha-
nisms. DNA methylation, where a methyl group is added 
to cytosine in the CpG context, is the most studied epige-
netic mechanism critical for processes such as genomic 
imprinting and X chromosome inactivation6 and also 
T-cell activation and differentiation.7–10 Two recent stud-
ies suggest subtle but numerous DNA methylation 
changes in CD4+ T cells of RR-MS patients.11,12
Besides DNA methylation, gene expression is regu-
lated by ncRNAs like microRNAs (miRNAs) that act 
post-transcriptionally.13 Mature miRNAs regulate mul-
tiple targets by recognizing a specific mRNA sequence 
in target mRNA. In T cells, miRNAs are involved in 
most processes and have important roles in T-cell acti-
vation and differentiation.14 A number of studies have 
profiled miRNAs in MS, and several miRNAs are now 
emerging as important regulators, one such being miR-
21.15 Expression of miR-21 in CD4+ T cells has been 
shown to negatively correlate with DNA methylation at 
the CpGs in the MIR21 gene.16
In this study, we sought to investigate DNA methyla-
tion in CD4+ T cells isolated from peripheral blood of 
RR-MS patients in remission, SP-MS patients, and 
healthy controls (HC).
Materials and methods
Full details of experimental procedures are provided 
in Supplementary Methods.
Cohorts
A discovery MS cohort and an independent cohort used 
for validation were recruited at the Neurology clinic at 
Karolinska University Hospital in Stockholm. Cohort 
details are provided in Table 1 and in Supplementary 
Table 1. The Regional Ethical Review Board in 
Stockholm approved this study (2009/2107-31/2 and 
2010/879-31/1), and methods were carried out in 
accordance with institutional guidelines on human sub-
ject experiments. Informed consent was obtained from 
all subjects.
The Genetics of Lipid Lowering Drugs and Diet 
Network (GOLDN) cohort recruited families with at 
least two siblings from the National Heart, Lung, and 
Blood Institute Family Heart Study sites at 
Minneapolis and Salt Lake City.17–19 The Institutional 
Review Board (IRB) approved the GOLDN study 
(E160405007).
Preparation of CD4+ T cells
For discovery and validation cohorts, peripheral 
blood mononuclear cells (PBMCs) were isolated 
using a standard Ficoll (GE Healthcare) and sodium 
citrate–containing preparation tubes (Becton 
Dickinson) procedures, respectively. Sorting of the 
CD4+ T cells was performed on a MoFlo™ cell sorter 
(Beckman Coulter) and an autoMACS® cell separa-
tor (Miltenyi Biotec), respectively. Extraction of 
genomic DNA was carried out using GenElute 
Mammalian Genomic DNA Miniprep kit (Sigma-
Aldrich). RNA was isolated using standard TRIzol 
protocol (Invitrogen) and Allprep Total RNA/DNA 
Kit (Qiagen), respectively.
DNA methylation analysis
DNA methylation was profiled using the Infinium 
HumanMethylation450 BeadChip (Illumina; referred 
as 450K hereinafter) arrays at the Bioinformatics and 
Expression Analysis (BEA) core facility at Karolinska 
Institutet. Methylation data were individually ana-
lyzed using the minfi and ChAMP package and nor-
malized using quantile normalization and Beta Mixture 
Quantile dilation (BMIQ). Differentially methylated 
positions were determined using the limma package 
applying a linear modeling that included MS status, 
age, and sex as covariates. A representative CpG was 
validated using pyrosequencing.
Transcriptome analysis
Total RNA was subjected to the Illumina TruSeq 
Stranded mRNA Library Protocol with Dual Indexes 
(Illumina) and sequenced on Illumina HiSeq 2500 to 
generate 75 bp paired-end data with an average of 
10 M reads above Q30. Differential expression analy-
sis was conducted using the limma package.
Expression of miR-21 was determined using 
TaqMan MicroRNA Assay Kit (No.: 000397, 
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Applied Biosystems), and VMP1 expression was 
assessed by quantitative polymerase chain reaction 
(qPCR) using SYBR green chemistry (Bio-Rad).
Genotyping
Allelic discrimination was performed using a prede-
signed TaqMan SNP Genotyping Assay (No.: 
4351379, Applied Biosystems).
Association, correlation, and meta-analysis
In the GOLDN cohort, we used the lmekin function 
of the R kinship package to fit linear mixed-effects 
models with the methylation β-value at each of the 
interrogated CpG sites as the outcome and different 
predictors.
In the MS cohort, we fit linear regression model in 
Rcmdr with the methylation β-value at each of the 
interrogated CpG sites as the outcome and different 
predictors.
We used two different meta-analysis methodologies: 
(1) the “summation of p value” method for combining 
p-values, and (2) the effect-size-based meta-analysis 
using a fixed-effects model (estimated by restricted 
maximum likelihood) since there was no evidence of 
heterogeneity.
Target gene enrichment analysis
Targets of miR-21 identified in Jurkat T cells by RIP-
Chip and predicted by TarBase7.0 were selected for 
analysis. Deviation of up-regulated and down-regulated 
Table 1. Patient demographics in the discovery cohort used for 450K methylation analysis.
Status Gender Age EDSS MSSS OCB MRI 
lesions
TAS TPS
RR-MS F 37 3 2.91 Yes 10–20 Never Tx  
RR-MS F 40 0 0.67 Yes >20 Never Tx  
RR-MS M 44 1.5 Yes >20 Never Tx  
RR-MS F 26 1 5.87 No 9 Never Tx  
RR-MS F 29 2 5.87 Yes >20 Never Tx  
RR-MS F 35 1 1.13 Yes >20 No Tx Fingolimod
RR-MS F 46 5 3.44 Yes >20 IVIg  
RR-MS F 37 1.5 3.34 Yes >20 SD  
RR-MS M 29 1 0.88 Yes >20 No Tx IFN
RR-MS M 32 3 3.05 Yes >20 No Tx IFN
RR-MS F 57 2.5 4.13 Yes >20 No Tx SD
RR-MS F 41 2 0.71 Yes >20 Never tx  
SP-MS M 45 4 2.82 Yes >20 No Tx IFN
SP-MS M 50 6.5 5.99 Yes 9 No Tx SD
SP-MS M 56 6.5 5.99 Yes 10–20 Never Tx  
SP-MS F 63 5 Yes >20 Never Tx  
SP-MS F 35 5 7.32 Yes >20 No Tx IFN, GA
SP-MS F 60 5 5.82 Yes >20 No Tx IFN, Mtx
SP-MS M 44 6 5.43 Yes >20 No Tx IFN, SD
SP-MS F 50 3.5 4.55 Yes >20 No Tx IFN
Summarized
 RR-MS 75%a 38 (26–57)b 2.0 (0–5.0)b 2.9 (0.7–5.9)b 92%c 17%d  
 SP-MS 50%a 50 (35–63)b 5.2 (3.5–6.5)b 5.4 (2.8–7.3)b 100%c 0%d  
 HC 67%a 42 (28–62)b N/A N/A N/A N/A  
RR: relapsing-remitting multiple sclerosis; SP: secondary-progressive multiple sclerosis; HC: healthy controls; F: female; M: male; EDSS: Expanded Disability 
Status Scale; MSSS: Multiple Sclerosis Severity Score; OCB: oligoclonal bands; MRI: magnetic resonance imaging; TAS: treatment at sampling; TPS: 
treatment prior to sampling; Tx: treatment; Never Tx: treatment naïve; No Tx: sampling after 6-month wash-out period; SD: study drug; IFN = interferon beta; 
GA: glatiramer acetate; Mtx: mitotrexate; N/A: not applicable; IVIg: intravenous Immunoglobulins.
aPercentage of females.
bMean (range).
cPercentage of OCB-positive patients.
dPercentage of patients treated at the time of sampling.
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miR-21 target genes from the expected ratio was calcu-
lated using the chi-square test. Enrichment of differen-
tially expressed targets among up-regulated and 
down-regulated genes was calculated using Fisher’s 
exact test.
Ingenuity pathway analysis
Upstream regulators and biological functions were 
determined in the ingenuity pathway analysis (IPA) 
platform (Qiagen) using Fisher’s exact test and right-
tailed Fisher’s exact test, followed by Benjamini–
Hochberg correction, respectively.
Results
CD4+ T cells from RR-MS patients display higher 
DNA methylation in the VMP1/MIR21 locus
We investigated DNA methylation in CD4+ T cells 
from a Swedish cohort comprising RR-MS, SP-MS, 
and matched HC. Analysis of 432,874 probes from 
the 450K did not yield genome-wide significant 
changes. However, among the top most significant 
hits, we observed multiple probes mapping to last two 
exons of VMP1 and MIR21 genes (Figure 1(a); Table 
2). RR-MS displayed significantly higher methylation 
compared to HC and SP-MS at the 11 consecutive 
CpG probes. The cg07181702 in MIR21, which was 
validated using pyrosequencing (Figure 1(a)), had the 
largest effect size of 14% methylation change between 
RR-MS and HC.
We sought to replicate our findings between RR-MS and 
HC (n = 24) in independent CD4+ T-cell cohorts com-
prising RR-MS from Australia (N = 40) and Norway 
(N = 30).11,12 Higher methylation in RR-MS was 
observed at all 11 CpGs in both cohorts (Figure 1(b)). Of 
the 11 CpGs, 9 and 4 displayed significant changes in the 
Norwegian and Australian cohort, respectively (Figure 
1(c)). Meta-analysis performed combining p-values and 
effect sizes from all three cohorts demonstrated signifi-
cant changes for all 11 CpGs (Figure 1(c)).
These data support higher methylation levels in the 
VMP1/MIR21 locus in RR-MS patients in three inde-
pendent cohorts.
Investigation of association between methylation 
levels in VMP1/MIR21 and MS risk factors
It has been shown that genetic variants can mediate 
disease risk through changes in DNA methylation,20 
and there is a well-established genetic association 
between MS and the VMP1 locus.4 Thus, we 
investigated whether genetic variation in VMP1 may 
mediate MS risk by affecting VMP1/MIR21 methyla-
tion levels. We detected significant differences in 
CD4+ T cells from healthy individuals in the GOLDN 
cohort (N = 717)17–19 for only 2 of 11 CpGs comparing 
individuals carrying none, one, or two of the 
RS8070345 risk alleles (Figure 2(a); Table 3) and no 
significant differences in the MS cohort (Figure 2(b); 
Table 4).
We then tested whether VMP1/MIR21 methylation 
levels mediate the effect of smoking, a well-estab-
lished risk factor for MS5 also known to affect DNA 
methylation.21 No consistent significant differences at 
any of the 11 CpGs between never, past, and current 
smokers were detected in the GOLDN cohort (Figure 
2(c); Table 3).
There was a tendency for a positive correlation with 
lymphocyte counts with 1/11 and 3/11 CpGs display-
ing p < 0.05 and p < 0.1, respectively (Figure 3(a); Table 
4). Additionally, methylation in VMP1/MIR21 dis-
played a strong negative correlation with age (e.g. for 
cg07181702, n = 32, Pearson’s r = –0.62, p < 0.0001) 
(Figure 3(b); Table 4), with higher methylation levels 
in CD4+ T cells of younger individuals, which was also 
detected in the GOLDN cohort (e.g. for cg07181702, 
n = 994, coefficient = –0.0011, p < 4 × 10–7) (Table 3).
Thus, increased methylation in VMP1/MIR21 is not 
caused by the genetic variation in the locus or smok-
ing, but instead age strongly affects VMP1/MIR21 
methylation.
Hypermethylation of the VMP1/MIR21 locus 
associates with lower expression of miR-21 in 
CD4+ T cells
There was a high correlation between methylation 
levels at all CpGs (Supplementary Figure 1), suggest-
ing that methylation changes in the region are co-reg-
ulated and likely have the same functional impact. We 
then investigated whether methylation in VMP1/
MIR21 has an impact on the expression of miR-21 
and VMP1, analyzed by qPCR in patients and HC 
from the MS cohort. We observed a significant nega-
tive correlation between methylation at 7/11 CpGs 
and miR-21 levels, with additional 4/11 CpGs dis-
playing the same trend (Figure 4(a); Table 5), while 
there was no correlation with VMP1 levels (Figure 
4(b); Table 5). This inverse correlation between meth-
ylation and miR-21 levels was strongest for the CpGs 
in MIR21 (e.g. for cg 07181702, n = 27, Pearson’s 
r = –0.51, p = 0.006) and remained significant after 
age correction (Table 5).
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Figure 1. CD4+ T cells from RR-MS patients display higher DNA methylation levels in the VMP1/MIR21 locus. (a) 
DNA methylation was measured using 450K arrays in CD4+ T cells sorted from peripheral blood of RR-MS (n = 12) 
and SP-MS (n = 8) patients and healthy controls (HC; n = 12). Eleven consecutive CpG sites (dashed box) displayed 
significantly higher methylation in RR-MS compared to SP-MS and HC. Detailed analysis of the locus is given in Table 
2. The CpGs map to the VMP1 gene (last two exons and intron) and MIR21 gene, the region that is enriched for active 
histone mark (H3K27Ac) in two immune cell lines (ENCODE: GM12878 and K562). The methylation difference at 
a selected CpG, cg07181702 in the MIR21 gene, was technically validated using pyrosequencing (right lower panel). 
(b) The effect size that represents a difference in β-values between RR-MS and HC at a given CpG displayed the same 
pattern of increased DNA methylation in RR-MS compared to HC at the 11 consecutive CpG sites in the Swedish 
(N = 24) cohort and two additional cohorts from Australia (N = 40)11 and Norway (N = 30).12 (c) Comparison of RR-MS 
with HC was performed on β-values and corrected for age in the Norwegian and Australian cohort (comprising females 
only), and age and sex in the Swedish cohort. Meta-analysis performed combining p-values (using the “summation of 
p value” method) and effect sizes (using fixed-effects model) yielded significant p-values for all 11 CpGs. Significance 
levels for each CpG in different analyses are given on the y-axis as a −log10(p-value).
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Accordingly, a tendency for decrease in the expression 
of miR-21 was observed in RR-MS patients compared 
to SP-MS and HC (Figure 4(c)). To validate our find-
ings, we performed expression analysis in an inde-
pendent MS cohort from Sweden including more cases 
(Supplementary Table 1). Significantly lower levels of 
miR-21 were detected in RR-MS patients compared to 
SP-MS patients and HC (Figure 4(d)).
These data strongly suggest that increased methyla-
tion in MIR21 associates with lower expression of 
mature miR-21 in CD4+ T cells of RR-MS patients.
MiR-21 target genes are enriched among genes 
up-regulated in CD4+ T cells of RR-MS patients
Since the best described function of miRNAs is to 
induce degradation of target mRNAs, we explored 
whether the observed changes in miR-21 methylation 
and expression lead to actual functional changes in 
miR-21 target genes. For that purpose, we used RNA-
seq data from a cohort largely overlapping (73%) the 
cohort used for 450K analysis (Supplementary Table 1). 
We used miR-21 targets identified in Jurkat T cells 
using RIP-Chip and predicted by TarBase7.0 
(Supplementary Table 2). We first investigated whether 
the ratio of up-regulated miR-21 targets deviated from 
the expected ratio of up-regulated genes between 
Table 2. DNA methylation changes in the VMP1/MIR21 locus in CD4+ T cells from RR-MS and SP-MS patients and 
HC.
Probe IDa Genea Featurea ALLb RR vs HCb RR vs SPb SP vs HCb
 p-val 
(M)
Eff 
(Δβ)
p-val 
(M)
Eff 
(Δβ)
p-val 
(M)
Eff 
(Δβ)
p-val 
(M)
cg20458044 VMP1 Intron 1E-01 0.04 2E-01 0.07 4E-02 –0.03 3E-01
cg16936953 VMP1 Exon 2E-03 0.06 6E-02 0.10 5E-04 –0.04 4E-02
cg12054453 VMP1 Exon 4E-03 0.03 9E-02 0.04 1E-03 –0.02 5E-02
cg01409343 VMP1 Exon 1E-02 0.06 7E-02 0.10 3E-03 –0.04 2E-01
cg18942579 VMP1 Intron 4E-04 0.08 1E-02 0.12 1E-04 –0.05 6E-02
cg02782634 VMP1 Intron 4E-03 0.10 5E-02 0.17 1E-03 –0.08 8E-02
cg14032089 MIR21 TSS1500 3E-02 0.09 7E-02 0.14 1E-02 –0.05 3E-01
cg27023597 MIR21 TSS1500 2E-04 0.12 2E-03 0.16 6E-05 –0.04 1E-01
cg04276626 MIR21 TSS200 7E-02 0.08 1E-01 0.12 3E-02 –0.04 4E-01
cg02515217 MIR21 TSS200 4E-03 0.12 2E-02 0.17 2E-03 –0.05 3E-01
cg15759721 MIR21 Body 9E-03 0.11 4E-02 0.14 3E-03 –0.04 2E-01
cg07181702 MIR21 Body 2E-03 0.14 7E-03 0.18 9E-04 –0.04 3E-01
cg22663389 – IGR 6E-01 –0.00 3E-01 –0.00 6E-01 –0.00 7E-01
MS: multiple sclerosis; RR: relapsing-remitting multiple sclerosis; SP: secondary-progressive multiple sclerosis; HC: healthy controls.
aCpG probe ID, annotated gene names and genomic features from 450K arrays.
bM-values (indicated by M) were used to compare RR-MS patients (RR; n = 12), SP-MS patients (SP; n = 8), and healthy controls 
(HC; n = 12), and p-values (p-val) were derived using a linear modeling that included MS status, age, and sex as covariates. The 
effect size (Eff) represents a difference in β-values (Δβ) between the groups for each probe. p-val <0.05 are indicated in bold.
Figure 2. MS risk factors, genetic variation in the VMP1 
gene and smoking, do not affect DNA methylation in the 
VMP1/MIR21 locus. DNA methylation levels (β-values) 
in the VMP1/MIR21 locus, exemplified by cg07181702, 
do not associate with the MS risk genotype at RS8070345 
(T = risk allele) in a (a) large cohort of healthy individuals 
or (b) in the Swedish cohort. Detailed analysis of the locus 
is given in Tables 3 and 4. (c) DNA methylation levels 
(β-values) in the VMP1/MIR21 locus, exemplified by 
cg07181702, are not affected by the smoking status in a 
large cohort of healthy individuals. Detailed analysis of the 
locus is given in Table 3.
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RR-MS, SP-MS, and HC (Table 6). There was a signifi-
cant enrichment of miR-21 targets among the genes that 
were up-regulated in CD4+ T cells, both when compar-
ing RR-MS patients with HC and when comparing 
RR-MS with SP-MS but not when SP-MS patients were 
compared with HC (Table 6). Similar results were 
obtained when we calculated enrichment of miR-21 tar-
gets among up-regulated and down-regulated genes 
where we found significant enrichment of miR-21 tar-
gets predominantly among up-regulated, but not down-
regulated, genes between RR-MS and HC (Table 7). 
Additionally, an unbiased IPA prediction of upstream 
Table 3. Influence of RS8070345, smoking, and age on DNA methylation in the VMP1/MIR21 locus in healthy 
individuals.
CpG probea Genea RS8070345b 
(N = 717)
Current smokerc 
(N = 994)
Past smokerc 
(N = 994)
Agec (N = 994) 
Coeff p-val Coeff p-val Coeff p-val Coeff p-val
cg16936953 VMP1 –0.0106 0.049 –0.0098 0.34 –0.0060 0.37 –0.0010 5E-07
cg12054453 VMP1 –0.0170 1E-04 –0.0158 0.07 –0.0120 0.031 –0.0005 4E-03
cg01409343 VMP1 –0.0046 0.43 0.0011 0.92 0.0002 0.97 –0.0011 2E-07
cg18942579 VMP1 –0.0086 0.13 0.0000 1.00 0.0020 0.78 –0.0011 3E-07
cg02782634 VMP1 0.0016 0.78 –0.0065 0.55 0.0007 0.92 –0.0010 5E-07
cg14032089 MIR21 0.0057 0.33 –0.0041 0.71 0.0019 0.79 –0.0009 2E-05
cg27023597 MIR21 –0.0058 0.34 –0.0126 0.28 0.0002 0.98 –0.0010 5E-06
cg04276626 MIR21 0.0032 0.58 –0.0057 0.59 0.0028 0.68 –0.0004 0.06
cg02515217 MIR21 0.0016 0.82 0.0022 0.85 –0.0001 0.99 –0.0012 3E-07
cg15759721 MIR21 0.0048 0.42 –0.0017 0.88 0.0019 0.79 –0.0010 1E-06
cg07181702 MIR21 0.0034 0.57 0.0011 0.92 0.0014 0.85 –0.0011 4E-07
aCpG probe ID and annotated gene names from 450K arrays.
b Coefficients (Coeff) and p-values (p-val) from a linear mixed-effects model with the methylation β-score at each CpG site as the 
outcome and the following predictors: genotype at RS8070345, age, sex, study site, current smoking, body mass index (BMI), 
principal components capturing T-cell purity, and family, as previously described.19 p-val <0.05 are indicated in bold.
c Coefficients (Coeff) and p-values (p-val) from a linear regression model with the methylation β-score at each CpG site as the 
outcome and the following predictors: age, current and past smoking, BMI, and principal components capturing T-cell purity, as 
previously described.19 p-val <0.05 are indicated in bold.
Table 4. Correlation of DNA methylation in the VMP1/MIR21 locus with patient characteristics.
CpG probea Genea RS8070345b (N = 27) Ly#c (N = 18) Agec (N = 18)
Coeff p-val Coeff p-val Coeff p-val
cg16936953 VMP1 –0.0076 0.59 0.0534 0.10 –0.0067 5E-05
cg12054453 VMP1 –0.0061 0.36 0.0178 0.37 –0.0027 3E-03
cg01409343 VMP1 0.0003 0.98 0.0788 0.078 –0.0070 2E-04
cg18942579 VMP1 –0.0013 0.94 0.0510 0.22 –0.0055 6E-03
cg02782634 VMP1 –0.0275 0.32 0.1077 0.12 –0.0096 2E-03
cg14032089 MIR21 –0.0111 0.69 0.0956 0.16 –0.0101 1E-03
cg27023597 MIR21 0.0090 0.67 0.1034 0.039 –0.0077 5E-04
cg04276626 MIR21 –0.0104 0.72 0.0955 0.15 –0.0103 8E-04
cg02515217 MIR21 –0.0162 0.56 0.0582 0.38 –0.0112 4E-04
cg15759721 MIR21 –0.0134 0.61 0.1116 0.082 –0.0086 2E-03
cg07181702 MIR21 –0.0053 0.84 0.0664 0.31 –0.0105 7E-04
aCpG probe ID and annotated gene names from 450K arrays.
bCoefficients (Coeff) and p-values (p-val) from a linear regression model with the methylation β-score at each CpG site as the 
outcome and the following predictors: age, sex, and genotype at RS8070345 (N = 27).
cCoefficients (Coeff) and p-values (p-val) from a linear regression model with the methylation β-score at each CpG site as the 
outcome and the following predictors: age, sex, and lymphocyte count (Ly#) (N = 18). p-val <0.05 are indicated in bold.
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regulators identified miR-21 as a significantly inhibited 
upstream regulator (z = –2.1, p = 7 × 10–7) in RR-MS that 
can explain the observed pattern of differential gene 
expression between RR-MS and HC (p < 0.05).
In order to identify biological functions that are regu-
lated by miR-21 in CD4+ T cells we performed IPA on 
TarBase7.0-predicted miR-21 targets that were up-
regulated in RR-MS compared to HC (p<0.05, n=30) 
(Supplementary Table 2). Despite a limited list of 
genes several functions were significant after 
Benjamini-Hochberg correction including “Apoptosis” 
(z=-1.624) and “Proliferation of cells” (z=1.007).
These analyses strongly suggest a link between lower 
miR-21 expression and up-regulation of a set of miR-
21 target genes in CD4+ T cells that potentially influ-
ence apoptosis and cell proliferation.
Discussion
We performed DNA methylation analysis in CD4+ T 
cells from RR-MS, SP-MS, and healthy individuals 
and subsequently characterized the relationship 
between MIR21 methylation and expression of miR-
21 and its target genes. MIR21 displayed increased 
methylation levels that correlated with a lower expres-
sion of mature miR-21 and an enrichment of up- 
regulated miR-21 target genes in RR-MS patients.
In order to assess the relevance of MIR21 hypermeth-
ylation in RR-MS, we investigated both the methyla-
tion of this locus in previously published MS cohorts 
and assessed potential functional impact of MIR21 
methylation using RNA-seq data. A similar pattern as 
in our study, that is, hypermethylation of all 11 CpGs 
in RR-MS, was observed in the Norwegian and 
Australian cohorts,11,12 with nine and four significant 
probes (p < 0.05), respectively (two additional probes 
from each cohort demonstrated p < 0.1). The most sig-
nificant changes were observed in the Norwegian 
cohort, which included untreated MS patients with 
relatively benign disease course12 that can potentially 
explain a more modest effect size of 6%–8% change 
in MIR21. The effect size was similar in the Swedish 
and Australian cohorts ranging from 8% to 14% and 
7% to 16%, respectively, but the changes were less 
significant in the Australian cohort potentially due to 
higher variability caused by treatments.11 It is impor-
tant to consider that all studies investigated bulk 
CD4+ T cells that comprise subsets with distinct 
methylomes,16,22 and methylation changes could 
reflect differences in their cellular composition. 
However, as MIR21 is hypomethylated in Th1/Th222 
and regulatory T cells (Tregs)16 compared to naïve 
CD4+ T cells, and naive CD4+ T cells display the 
lowest expression of miR-21 compared to other CD4+ 
subsets,14 the differences in frequency are less likely 
to explain hypermethylation in RR-MS.
Figure 3. DNA methylation in the VMP1/MIR21 locus 
displays strong negative correlation with age. DNA 
methylation levels (β-values) in the VMP1/MIR21 locus, 
exemplified by cg07181702, do not show significant 
association with (a) lymphocyte count, as a surrogate 
of inflammation levels, but display a significant strong 
negative correlation with (b) age. Detailed analysis of the 
locus is given in Table 4.
Figure 4. DNA methylation in the VMP1/MIR21 locus 
displays significant negative correlation with miR-21 
expression, and RR-MS patients display lower miR-21 
levels. DNA methylation levels (β-values) in the VMP1/
MIR21 locus, exemplified by cg07181702, display a 
significant strong anti-correlation with (a) miR-21 levels 
but not with (b) VMP1 levels in CD4+ T cells from RR-
MS, SP-MS and healthy controls (HC). Accordingly, 
RR-MS patients have lower levels of miR-21 compared to 
HC and SP-MS patients in the (c) 450K cohort and in an 
(d) independent validation cohort from Sweden. Detailed 
analysis of the locus is given in Table 5.
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Table 5. Correlation of DNA methylation in the VMP1/MIR21 locus with miR-21 and VMP1 expression levels.
CpG probea Genea miR-21b (N = 27) VMP1b (N = 27)
r p-val Coeff p-val r p-val
cg16936953 VMP1 –0.34 0.083 –3.49 0.14 –0.02 0.91
cg12054453 VMP1 –0.23 0.24 –3.84 0.42 0.02 0.90
cg01409343 VMP1 –0.40 0.038 –3.85 0.054 –0.06 0.77
cg18942579 VMP1 –0.32 0.108 –2.53 0.21 0.09 0.66
cg02782634 VMP1 –0.42 0.027 –2.39 0.042 –0.11 0.57
cg14032089 MIR21 –0.38 0.047 –2.11 0.081 –0.08 0.70
cg27023597 MIR21 –0.35 0.076 –2.50 0.12 0.13 0.52
cg04276626 MIR21 –0.54 0.004 –3.08 0.006 –0.04 0.82
cg02515217 MIR21 –0.43 0.025 –2.82 0.029 0.08 0.68
cg15759721 MIR21 –0.50 0.008 –3.20 0.013 –0.06 0.76
cg07181702 MIR21 –0.51 0.006 –3.32 0.006 –0.04 0.83
RR: relapsing-remitting multiple sclerosis; SP: secondary-progressive multiple sclerosis; HC: healthy controls.
aCpG probe ID and annotated gene names from 450K arrays.
b Pearson’s r and regression coefficients (Coeff), with accompanying p-values (p-val), from a Pearson correlation test, for relative 
expression of miR-21 and VMP1, and a linear regression model with the relative expression of miR-21 as the outcome and 
methylation β-score at each CpG site and age as predictors. p-val < 0.05 are indicated in bold. Analysis was performed in CD4+ T 
cells from RR-MS, SP-MS, and HC.
Table 6. Deviation of the miR-21 target genes from the expected ratio of the up-regulated genes in CD4+ T cells from 
RR-MS and SP-MS patients and HC.
Predictiona Comparisona DEb (p-val) Groupb UP obsb (%) UP expb (%) p-valb
Jurkat (N = 64) RR vs HC 0.01 RR 100 53 0.1
0.05 RR 80 44 0.02
0.1 RR 86 43 0.001
RR vs SP 0.01 RR – 35  
0.05 RR 100 34 0.006
0.1 RR 78 37 0.01
SP vs HC 0.01 SP 100 63 0.4
0.05 SP 100 58 0.1
0.1 SP 78 56 0.2
TarBase (N = 433) RR vs HC 0.01 RR 90 53 0.02
0.05 RR 65 44 0.004
0.1 RR 61 43 0.002
RR vs SP 0.01 RR 75 35 0.09
0.05 RR 64 34 0.004
0.1 RR 68 37 0.00001
SP vs HC 0.01 SP 50 63 0.5
0.05 SP 52 58 0.5
0.1 SP 52 56 0.6
RR: relapsing-remitting multiple sclerosis; SP: secondary-progressive multiple sclerosis; HC: healthy controls.
aTarget genes of miR-21 identified in Jurkat T cells (N = 64, 100% present in RNA-seq data) and genes predicted and experimentally 
validated to be miR-21 targets by TarBase7.0 (N = 433, 88% present in RNA-seq data) were selected for analysis.
b Differentially expressed (DE) genes between RR-MS patients (RR; n = 12), SP-MS patients (SP; n = 10), and healthy controls (HC; 
n = 12) were identified using RNA-seq (significance for calling DE is indicated by DE (p-val)). For each comparison, a deviation of 
the percentage of the observed up-regulated miR-21 target genes (UP obs), in a given group (Group), from the expected percentage 
of the up-regulated genes (UP exp) was calculated using a chi-square test (p-val). p-val <0.05 are indicated in bold.
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We further demonstrated a functional impact of the 
observed methylation on the expression of miR-21. 
The higher methylation levels in VMP1/MIR21 cor-
related strongly with lower expression of mature 
miR-21 in CD4+ T cells, whereas no correlation was 
observed with VMP1. The negative correlation with 
miR-21 levels was the strongest at the CpGs in the 
MIR21 gene. Methylation at the same CpGs has pre-
viously been shown to negatively correlate with miR-
21 expression in naïve CD4+ T cells upon activation.16 
Accordingly, we observed lower expression of mature 
miR-21 in RR-MS patients compared to SP-MS and 
controls, and this difference became significant in a 
larger independent cohort. The difference between 
RR-MS and SP-MS, however, may reflect differences 
in age between the groups since MIR21 methylation 
displays a strong negative correlation with age.
Consistent with the function of miRNAs in down-regu-
lating their target genes, we found miR-21 targets 
enriched among up-regulated genes in RR-MS patients. 
The enrichment was significant irrespective of the tar-
get prediction tool, the cut-off levels for differential 
expression, and the enrichment analysis approach used. 
Importantly, the enrichment was detected only in 
RR-MS, which is in line with the observed higher meth-
ylation and lower expression of miR-21 in RR-MS 
compared to HC or SP-MS and no difference between 
HC and SP-MS. The most prominent biological func-
tions that associated with the up-regulated targets imply 
possible anti-apoptotic and pro-proliferative effects. 
Representatives for such genes are DEGS1, PTPN13, 
and CD47 that have been shown to inhibit apoptosis and 
increase proliferation in different cells. For instance, 
DEGS1, enzyme involved in the ceramide synthesis, 
has been shown to increase proliferation and decrease 
apoptosis in mammalian cells.23 In CD4+ T cells, cera-
mides have been implicated in regulating T-cell prolif-
eration and differentiation into Th1.24 Overexpression 
of PTPN13, a protein tyrosine phosphatase, leads to 
increased resistance to FAS-induced apoptosis in 
immortalized T cells.25 The ligation of CD47, a plasma 
membrane protein, leads to an increase in interleukin 
(IL)-2 production and more proliferation in primary and 
Jurkat T cells.26 Gene deletion or blocking of CD47 pro-
tects against development of MS-like disease in mice 
through a failure of immune cell activation.27 In relation 
to these observations, our data suggest a potential role 
Table 7. Overlap of miR-21 target genes with up-regulated and down-regulated genes in CD4+ T cells from RR-MS and 
SP-MS patients and HC.
Predictiona Comparisona DE (p-val)b p-val (UP)b p-val (DOWN)b
Jurkat (N = 64) RR vs HC 0.01 0.06 0.8
0.05 0.003 0.6
0.1 0.0009 0.1
RR vs SP 0.01 - -
0.05 0.1 0.1
0.1 0.06 0.2
SP vs HC 0.01 0.9 0.7
0.05 0.4 0.4
0.1 0.3 0.6
TarBase (N = 433) RR vs HC 0.01 0.09 0.2
0.05 0.0005 0.4
0.1 0.003 0.1
RR vs SP 0.01 0.8 0.7
0.05 0.2 0.02
0.1 0.003 0.002
SP vs HC 0.01 0.8 0.6
0.05 0.9 0.3
0.1 0.3 0.1
RR: relapsing-remitting multiple sclerosis; SP: secondary-progressive multiple sclerosis; HC: healthy controls.
aTarget genes of miR-21 identified in Jurkat T cells (N = 64, 100% present in RNA-seq data) and genes predicted and experimentally 
validated to be miR-21 targets by TarBase7.0 (N = 433, 88% present in RNA-seq data) were selected for analysis.
bDifferentially expressed (DE) genes between RR-MS patients (RR; n = 12), SP-MS patients (SP; n = 10), and healthy controls (HC; 
n = 12) were identified using RNA-seq (significance for calling DE is indicated by DE (p-val)). For each comparison, an overlap of 
miR-21 target genes with either up-regulated (UP) or down-regulated (DOWN) genes was calculated using Fisher’s exact test (p-
val). p-val <0.05 and <0.1 are indicated in bold and italic bold, respectively. 
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of methylation-dependent miR-21 expression in modu-
lating proliferation and apoptosis of CD4+ T cells in 
RR-MS.
Expression of miR-21 is increased in many inflamma-
tory diseases, and elevated miR-21 levels represent a 
sign of inflammation.16,28 In MS, miR-21 has been 
found to be up-regulated in PBMCs of RR-MS patients 
in relapse, suggesting that hypermethylation of MIR21 
may be a mechanism to down-regulate miR-21 that 
may contribute to remission.29 However, another longi-
tudinal study did not report differences in miR-21 
expression in peripheral blood leukocytes from RR-MS 
patients in relapse and remission, but did observe 
down-regulation of miR-21 in RR-MS patients in 
remission compared to controls,30 which is similar to 
our observation. Regarding T cells, miR-21 has been 
shown to both promote and inhibit T-cell activation.31,32 
Overexpression of miR-21 in naïve mouse T cells pro-
motes expression of Th2 and Treg genes33 and expres-
sion of FoxP3 in human Tregs.34 Accordingly, lower 
expression of miR-21 has been reported in PBMCs and 
CD4+ T cells of rheumatoid arthritis patients compared 
to controls, with low miR-21 showing strong correla-
tion with an increased ratio of Th17/Treg cells.35 
Arguably, miR-21 may play different roles in different 
stages of disease depending on the stage of CD4+ 
T-cell activation and the cell subset.
We also investigated potential causes of the observed 
changes in DNA methylation. Since MIR21 resides in 
the locus that associates with susceptibility to MS,4 we 
first investigated whether methylation of MIR21 is 
genetically regulated. However, we found no consist-
ent evidence of association of the risk variant with the 
levels of MIR21 methylation. Similarly, we found no 
influence of smoking, which is known to induce DNA 
methylation changes21 and is an established lifestyle 
MS risk factor.5 One possibility is that MIR21 methyla-
tion and expression are regulated by the inflammation 
itself. The fact that miR-21 expression does not differ 
in SP-MS but shows low expression in RR-MS and 
inflammatory neurological disease controls supports 
this scenario. This is further supported by the observed 
trend for positive correlation between methylation and 
lymphocyte counts, as a surrogate of inflammation. 
However, none of the known proinflammatory regula-
tors of miR-2128 were differentially expressed between 
RR-MS and SP-MS patients or HC, suggesting that 
maybe differential methylation in their binding sites in 
MIR21 may lead to differences in miR-21 expression. 
Whether this is the case and the exact mechanisms of 
how inflammatory signals induce epigenetic repression 
in the locus need to be established.
To our knowledge, this is the first study that delivers 
a detailed description of the methylation status of 
MIR21 in CD4+ T cells of MS patients and associates 
it with the nearby risk allele, smoking, age, and 
changes in expression of miR-21 and its target genes. 
Our study sheds further light on the role of miR-21 in 
inflammatory diseases, in particular MS, demonstrat-
ing that disease-related changes in an epigenetic 
marking have the potential to lead to differences in 
the expression of miR-21 with a consequence on 
miR-21 target genes.
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